Gastrointestinal stromal tumours - imatinib (adjuvant) (rev TA196) [ID696]: evaluation report

Table of Contents:

1. Response to CC and public comments on the ACD
2a. Novartis comments on ACD
2b. BSG & Sarcoma UK joins comments on ACD


Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.

It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this appraisal.

This page was last updated: 16 October 2014